EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Baseline PET/CT Radiomics and Clinical Indicators for Pretreatment Response Prediction in Unresectable Hepatocellular Carcinoma: Model Development and Internal Validation

Yiwen Cheng iD, Cailong Chen iD, Yanyan Tang iD, Yanqing Xu iD, Juanzhen Huang iD, Qu Mo iD, Fuqi Xu iD, Dingluan Lin iD

Technology in Cancer Research & Treatment · 2026

DOI: 10.1177/15330338261495839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2026. Verfasst von Yiwen Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Radiomics, Carcinoma, Hepatocellular, Liver Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pretreatment prediction of benefit from targeted therapy plus immunotherapy remains uncertain in unresectable hepatocellular carcinoma (HCC). We developed and internally validated a model integrating baseline 18F-FDG PET/CT radiomics with clinical indicators.

Methods

This single-center retrospective study included 325 patients, comprising a development cohort (n = 182) and an internal validation cohort (n = 143). Clinical/PET, radiomics, and fusion logistic models were developed to predict 12-week objective response assessed according to the modified Response Evaluation Criteria in Solid Tumors. Development-derived preprocessing parameters, coefficients, and cutoffs were applied unchanged to validation. Discrimination was assessed using AUCs with bootstrap 95% confidence intervals and paired patient-level bootstrap comparisons; calibration was assessed using the Brier score, calibration intercept, and calibration slope.

Results

In the 143-patient internal validation cohort, the clinical, radiomics, and fusion models had AUCs of 0.69 (0.60-0.77), 0.75 (0.67-0.83), and 0.84 (0.78-0.90), respectively. The paired AUC difference was 0.16 (95% CI, 0.05 to 0.26; P = 0.002) versus the clinical model and 0.09 (-0.001 to 0.19; P = 0.053) versus the radiomics model. The fusion-model Brier score was 0.16, calibration intercept was -0.02, and calibration slope was 0.83.

Conclusion

The fusion model integrating clinical and radiomics features demonstrated favorable discrimination and calibration for predicting 12-week objective response in patients with HCC. It improved predictive performance compared with the clinical model alone and may provide a noninvasive tool for pretreatment response assessment. Prospective multicenter studies are warranted to evaluate its generalizability and clinical utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiomicsCarcinoma, HepatocellularLiver NeoplasmsPositron Emission Tomography Computed TomographyHumansFemaleMaleMiddle AgedRetrospective StudiesAgedPrognosisTreatment OutcomeROC CurveFluorodeoxyglucose F18

Stichwörter der Autor:innen

PET/CThepatocellular carcinomaimmunotherapyprediction modelradiomicstargeted therapy

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China.

ORCID-Profile: Yiwen Cheng, Cailong Chen, Yanyan Tang, Yanqing Xu, Juanzhen Huang, Qu Mo, Fuqi Xu, Dingluan Lin

Zitieren

APA

Cheng, Y., Chen, C., Tang, Y., Xu, Y., Huang, J., Mo, Q., Xu, F., & Lin, D. (2026). Baseline PET/CT Radiomics and Clinical Indicators for Pretreatment Response Prediction in Unresectable Hepatocellular Carcinoma: Model Development and Internal Validation. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338261495839

Vancouver

Cheng Y, Chen C, Tang Y, Xu Y, Huang J, Mo Q, et al. Baseline PET/CT Radiomics and Clinical Indicators for Pretreatment Response Prediction in Unresectable Hepatocellular Carcinoma: Model Development and Internal Validation. Technology in Cancer Research & Treatment. 2026. doi:10.1177/15330338261495839

BibTeX
@article{Cheng2026,
  author = {Cheng, Yiwen and Chen, Cailong and Tang, Yanyan and Xu, Yanqing and Huang, Juanzhen and Mo, Qu and Xu, Fuqi and Lin, Dingluan},
  title = {Baseline PET/CT Radiomics and Clinical Indicators for Pretreatment Response Prediction in Unresectable Hepatocellular Carcinoma: Model Development and Internal Validation},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  doi = {10.1177/15330338261495839}
}
Kostenlos starten →